Abstract
As part of our internal review, we identified a point to be clarified in the methods. The omitted step involves the reclassification of all deaths to the most severe category of outcome trajectories (trajectory group 5), and corresponding reclassification of non-deaths in this category to the adjacent, less severe category (trajectory group 4). This is implied by our use of the descriptor ‘fatal’ for the most severe category, but our description of methods omits the step to reclassify participants. We have included the following in the Statistics paragraph of the online version: To ensure that the most severe group contained only deaths, a final step was to reclassify any participant that died within 28 days after enrollment in the most severe group, and to reclassify any non-deaths in this group to the adjacent, next-most-severe group. We have confirmed the following: • Although the description of methods can be clarified, the stated results, discussion, and conclusions from our study remain unchanged.• The publicly available data are accurate. The publicly available analysis code has been updated and replicates our published results.The authors would like to apologise for any inconvenience caused.
Original language | English (US) |
---|---|
Article number | 104860 |
Journal | EBioMedicine |
Volume | 98 |
DOIs |
|
State | Published - Dec 2023 |
ASJC Scopus subject areas
- General Biochemistry, Genetics and Molecular Biology